

IN THE CLAIMS

Claims 1-32 (cancelled).

33. (currently amended) A method of treating a disease requiring regulation of cytokine production, a disease requiring nitrogen monoxide production, autoimmune disease, anemia, diabetes, septic shock, inflammatory enteropathy, chronic articular rheumatism, multiple sclerosis, uveitis or an allergic disease, wherein the method comprises administering a fucoidan derived from *Kjellmaniella crassifolia* and/or a degradation product thereof to a subject in need thereof for treating a disease requiring regulation of cytokine production, a disease requiring nitrogen monoxide production, said autoimmune disease, anemia, diabetes, septic shock, inflammatory enteropathy, chronic articular rheumatism, multiple sclerosis, uveitis or an said allergic disease.

34-36. (cancelled)

37. (currently amended) The method according to claim 33, wherein the allergic disease is a an allergic disease requiring suppression of IgE production.

38. (previously presented) The method according to claim 33, wherein the fucoidan and/or a degradation product thereof are orally administered.

39-60. (cancelled)

61. (new) The method according to claim 33, wherein a food, drink or feed containing the fucoidan and/or a degradation product thereof as an effective ingredient is used.

62. (new) The method according to claim 33, wherein a cosmetic containing the fucoidan and/or a degradation product thereof as an effective ingredient is used.

63. (new) The method according to claim 62, wherein the cosmetic is percutaneously administered.